Exploiting and defining the immune regulatory activities of BET bromodomain inhibitors

开发和定义 BET 溴结构域抑制剂的免疫调节活性

• 批准号: nhmrc : 1123432
• 负责人: A/Pr Jake Shortt
• 金额: $ 61.56万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/exploiting-defining-immune-bromodomain-inhibitors/947167
• 关键词: Exploiting; defining; immune; regulatory; activities

Immune-based agents such as “checkpoint inhibitors” have the ability to re-awaken our own immune systems and activate previously dormant anti-tumor responses. We have discovered that small molecule inhibitors of gene regulatory proteins called bromodomain proteins act synergistically with checkpoint inhibitors in mouse cancer models. We will define the molecular and biological events underpinning this novel combination approach and assess the effects of the combination across different tumors.

基于免疫的药物，例如“检查点抑制剂”，能够重新唤醒我们自身的免疫系统，并激活之前休眠的抗肿瘤反应。我们发现，在小鼠癌症模型中，基因调节蛋白（称为溴结构域蛋白）的小分子抑制剂与检查点抑制剂具有协同作用。我们将定义支持这种新型组合方法的分子和生物学事件，并评估该组合在不同肿瘤中的效果。